Multidimensional Assessment of Chronic Pain in Severe Haemophilia A

Launched by INVESTIGACIÓN EN HEMOFILIA Y FISIOTERAPIA · Jul 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how ongoing pain affects men with severe haemophilia A, a genetic bleeding disorder that mainly causes joint bleeds in areas like the knees and ankles. Even when treated with special medications called bispecific monoclonal antibodies, some patients still experience long-lasting pain. The study aims to understand how this persistent pain relates to feelings like worry about pain, confidence in managing the disease and treatment, and how patients see their bodies and any visible disabilities.

Men over 18 years old with severe haemophilia A who have been on this antibody treatment for at least three months may be eligible, especially if they have joint damage in their legs and can fill out questionnaires. Participants will be asked to complete surveys about their pain, emotions, and self-confidence. This study will help doctors learn more about how pain affects daily life beyond just preventing bleeds, which could lead to better support and care for people living with haemophilia. The trial is not yet recruiting and is open to adult men meeting these criteria.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age.
• • With a medical diagnosis of severe haemophilia A (FVIII \< 1%).
• • No inhibitors to FVIII concentrates at the time of the study.
• • At least 3 months of treatment with bispecific monoclonal antibodies.
• • Medical diagnosis of haemophilic arthropathy in at least two lower limb joints and ≥5 points on the Haemophilia Joint Health Score.
• • Ability to understand and respond to self-administered questionnaires.
• Exclusion Criteria:
• • Patients diagnosed with severe musculoskeletal or neurological comorbidities causing chronic pain.
• • Individuals with neurological or cognitive impairments that prevent them from understanding the questionnaires.
• • Patients who have participated in an interventional clinical study in the 6 months prior to the study.